This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
, No Gclids
Disease Info Card
Thrombotic Microangiopathies
Information about Thrombotic Microangiopathies: characteristics, related genes and pathways, plus antibodies you can use for research. This page is being enriched constantly, if you see some information you would like this page to include please send your suggestions to us.
Overview of Thrombotic Microangiopathies
Most recent studies have shown that Thrombotic Microangiopathies shares some biological mechanisms with acute-kidney-injury, anemia, anemia-hemolytic, disease-of-capillaries, hemolytic-uremic-syndrome, hypertensive-disease, kidney-diseases, kidney-failure, kidney-failure-acute, kidney-failure-chronic, lupus-erythematosus-systemic, malignant-neoplasms, microangiopathic-hemolytic-anemia, neoplasms, purpura, purpura-thrombotic-thrombocytopenic, thrombocytopenic-purpura, thrombosis, uremia-syndrome, von-willebrand-disease.
Among the many pathways, these few ones have gauged particular interests from scientists studying Thrombotic Microangiopathies, and have been seen in publications frequently: Angiogenesis, Cell Activation, Cell Death, Cell Proliferation, Coagulation, Complement Activation, Endothelial Cell Activation, Excretion, Fibrinolysis, Glomerular Filtration, Hemostasis, Immune Response, Inflammatory Response, Localization, Pathogenesis, Platelet Activation, Platelet Aggregation, Proteolysis, Secretion, Vasoconstriction
Quite a number of genes have been found to play important roles in Thrombotic Microangiopathies, such as ACE, ADAMTS13, AP3B1, C3, CABIN1, CD46, CFH, CFI, F2, F3, HP, IL6, PREP, SH3BP4, THBD, TNF, VEGFA, VWF, ZFP36. See what Boster has to offer for the research of these genes by clicking the gene name links below and view a more detailed info card/product listing for that gene.
In a later update, we will include information such as current drugs and therapy solutions as well as on-going and past clinical trials for this disease. Plesae stay updated.